joe rogan bpc 157 recommendation The “Wolverine peptide” is often described online as a powerful regenerative option — but what does that actually mean? We unpack what's typically included in this peptide stack, why it's drawn interest Joe Rogan and Human Biologist

Injectable BPC-157 Standard dose range: 200500 mcg per day Administration: Subcutaneous injection, once daily or split into two doses Cycle length: Typically 412 weeks, followed by an assessment period Injection site: Abdominal subcutaneous tissue

Always remember to remove air bubbles from the pin by flicking it gently, pin side up, and pushing bubbles out

Summary of REDEFINE 1 and REDEFINE 2 trials with CagriSema, presented this week at #ADA2025 and published in NEJM: REDEFINE 1: 3,417 participants with obesity or overweight (without diabetes) treated with CagriSema achieved a 22.7% weight loss after 68 weeks, compared to 2.3% with placebo 40.4% of participants on CagriSema achieved a weight loss of 25% or more The weight loss was slightly below the company's initial expectations of at least 25% REDEFINE 2: 1,206 participants with obesity or overweight and type 2 diabetes treated with CagriSema achieved a 15.7% weight loss after 68 weeks, best in the category thus far , compared to 3.1% with placebo 89.7% of participants achieved a weight loss of 5% or more Mean HbA1c reduction of 2.07% Article links: nejm.org/doi/full/10.10 nejm.org/doi/full/10.10 Summary of REDEFINE 1 and REDEFINE 2 trials with CagriSema, presented this week at #ADA2025 and published in NEJM: REDEFINE 1: 3,417 participants with obesity or overweight (without diabetes) treated with CagriSema achieved a 22.7% weight loss after 68 weeks, compared to 2.3% with placebo 40.4% of participants on CagriSema achieved a weight loss of 25% or more The weight loss was slightly below the company's initial expectations of at least 25% REDEFINE 2: 1,206 participants with obesity or overweight and type 2 diabetes treated with CagriSema achieved a 15.7% weight loss after 68 weeks, best in the category thus far , compared to 3.1% with placebo 89.7% of participants achieved a weight loss of 5% or more Mean HbA1c reduction of 2.07% Article links: nejm.org/doi/full/10.10 nejm.org/doi/full/10.10 Hopefully primary prevention in normal weight is next Pharma has obesity in its sights

Veterinary and human cartilage research reported in registry data

DSIP is discussed as a signaling peptide that may affect sleep timing and the stress response